TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27067068

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (N = 88), administered in five weekly 90-min sessions.
Number of subjects: 170

Group type: COMPARATOR
Intervention: Usual care control group (N = 82).
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (N = 88).
Number of subjects: 170
Study: 25118119

Group type: EXPERIMENTAL
Intervention: Pharmacoinvasive management
Number of subjects: 1051

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 1051
Study: 23680352

Group type: EXPERIMENTAL
Intervention: Moderate-to-severe diarrhoea
Number of subjects: 9439

Group type: EXPERIMENTAL
Intervention: ST-ETEC
Number of subjects: 9439

Group type: EXPERIMENTAL
Intervention: Typical enteropathogenic E. coli
Number of subjects: 9439

Group type: EXPERIMENTAL
Intervention: Cryptosporidium
Number of subjects: 9439

Group type: COMPARATOR
Intervention: Control group (children without diarrhoea)
Number of subjects: 9439
Study: 19933915

Group type: EXPERIMENTAL
Intervention: Vinorelbine plus cisplatin
Number of subjects: 482

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 482
Study: 18423274

Group type: EXPERIMENTAL
Intervention: Detailed document of informed consent disclosing possible risks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Simplified version of informed consent
Number of subjects: 60
Study: 15722903

Group type: EXPERIMENTAL
Intervention: Attenuation correction using Hawkeye low‐resolution X‐ray computed tomography
Number of subjects: 94

Group type: COMPARATOR
Intervention: Non-corrected images
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Attenuation correction
Number of subjects: 94
Study: 14514531

Group type: EXPERIMENTAL
Intervention: Strength training (S)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Proprioception training (P)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Strength + proprioception training (B)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 38
Study: 10534248

Group type: EXPERIMENTAL
Intervention: 5,000 U of BoNT/B
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: 10,000 U of BoNT/B
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: BoNT/B (both doses)
Number of subjects: 109
Study: 8550773

Group type: EXPERIMENTAL
Intervention: GLP-1-(7-36) amide (1.2 pmol/kg.min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl with 1% human serum albumin)
Number of subjects: 8
Study: 2065808

Group type: EXPERIMENTAL
Intervention: Short hCG/oocyte retrieval interval (34 hours) with immediate insemination
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Long hCG/oocyte retrieval interval (39 hours) with immediate insemination
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Short hCG/oocyte retrieval interval (34 hours) with delayed insemination (after 5 hours)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Long hCG/oocyte retrieval interval (39 hours) with delayed insemination (after 5 hours)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Preincubation before insemination
Number of subjects: 60
Study: 7092498

Group type: EXPERIMENTAL
Intervention: 1 mg of DE gamma E intramuscularly (IM) daily for ten days
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 10 mg of DE gamma E intramuscularly (IM) daily for ten days
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 3 mg of DE gamma E IM daily for ten days
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 30914185

Group type: EXPERIMENTAL
Intervention: Pre-eclampsia mobile application
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 110
Study: 28965346

Group type: EXPERIMENTAL
Intervention: Hypoxic condition (HYPO; FiO2, 14.5%)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Normoxic condition (NOR; FiO2, 20.9%)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 19
Study: 27091951

Group type: EXPERIMENTAL
Intervention: Group Triple P training
Number of subjects: 81

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 81
Study: 25229168

Group type: EXPERIMENTAL
Intervention: Valsartan (80 mg once a day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Amlodipine (5 mg once a day)
Number of subjects: 20
Study: 23011378

Group type: EXPERIMENTAL
Intervention: Clarithromycin (250 mg/day for 3 months) with topical corticosteroid treatment
Number of subjects: 112
Study: 19605972

Group type: EXPERIMENTAL
Intervention: First-line drugs (benzodiazepines: lorazepam, diazepam)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second-line drugs (phenytoin, fosphenytoin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Refractory status epilepticus treatments (barbiturates: phenobarbital, pentobarbital, thiopental; valproate; midazolam; propofol; isoflurane)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generalized convulsive status epilepticus
Number of subjects: 0
Study: 17477769

Group type: EXPERIMENTAL
Intervention: Physician's recommendation for testing
Number of subjects: 533
Study: 14994883

Group type: EXPERIMENTAL
Intervention: Headgear (HG) treatment for 16 months
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group with only interceptive procedures
Number of subjects: 68
Study: 11352393

Group type: EXPERIMENTAL
Intervention: 4% amethocaine gel (Ametop)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 5% eutectic mixture of lidocaine and prilocaine (EMLA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: E45 cream (placebo)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8204495

Group type: EXPERIMENTAL
Intervention: Epidural morphine 80 micrograms/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Epidural morphine 80 micrograms/kg plus butorphanol 40 micrograms/kg
Number of subjects: 0
Study: 3445800

Group type: EXPERIMENTAL
Intervention: Nova T (NTCu200Ag) IUD
Number of subjects: 800

Group type: COMPARATOR
Intervention: Multiload 250 (MLCu250) IUD
Number of subjects: 800
Study: 31094331

Group type: COMPARATOR
Intervention: Guided i-RFCBT
Number of subjects: 235

Group type: COMPARATOR
Intervention: Unguided i-RFCBT
Number of subjects: 235
Study: 28318984

Group type: EXPERIMENTAL
Intervention: Medical therapy plus neurovascular thrombectomy (Solitaire FR)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 206
Study: 25603459

Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/d)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 428
Study: 24417601

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Sertraline (SRT)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Combination of CBT and Sertraline (COMB)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Medication management with pill placebo (PBO)
Number of subjects: 488
Study: 22935042

Group type: EXPERIMENTAL
Intervention: Extra protein (33 g whey protein/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fast-food meal (1350 kcal, 41 g protein)
Number of subjects: 24
Study: 19324370

Group type: EXPERIMENTAL
Intervention: Significant cough
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Nose symptoms
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Insignificant cough
Number of subjects: 238
Study: 17543376

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) for 18 months
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo for 18 months
Number of subjects: 56
Study: 15389420

Group type: EXPERIMENTAL
Intervention: Brief screener using scales from the National Cancer Institute (NCI) Percent Energy from Fat Screener and 5‐A‐Day trials
Number of subjects: 203
Study: 11475558

Group type: EXPERIMENTAL
Intervention: BALF-ACE activity in patients with sarcoidosis
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Serum antibodies against 38 kDa
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Serum ACE activity
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Serum CEA concentration
Number of subjects: 40

Group type: COMPARATOR
Intervention: BALF-ACE activity
Number of subjects: 40

Group type: COMPARATOR
Intervention: Serum antibodies against 38 kDa and ACE activity
Number of subjects: 40
Study: 9806257

Group type: EXPERIMENTAL
Intervention: 2.5 mg per day Org OD 14 (tibolone) for 3 months
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (multi-vitamin pill) for 3 months
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Tibolone treatment
Number of subjects: 18
Study: 7699827

Group type: EXPERIMENTAL
Intervention: Paramedian approach (Group P)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Median approach (Group M)
Number of subjects: 71
Study: 2529112

Group type: EXPERIMENTAL
Intervention: Intra-arterial therapy (0.2 mg/kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intra-arterial (0.21 mg/kg) plus intravenous (0.09 mg/kg) therapy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 767366

Group type: EXPERIMENTAL
Intervention: Test group - patients recalled once every second week for professional tooth cleaning
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group - patients recalled once every 12 months for prophylaxis
Number of subjects: 24
Study: 31231803

Group type: EXPERIMENTAL
Intervention: Teacher-child race/ethnicity matching
Number of subjects: 5200

Group type: COMPARATOR
Intervention: Teacher-child mismatch in low-diversity classrooms
Number of subjects: 5200

Group type: COMPARATOR
Intervention: Teacher-child mismatch in high-diversity classrooms
Number of subjects: 5200
Study: 31556787

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 45

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 45
Study: 28814455

Group type: EXPERIMENTAL
Intervention: Usual care supplemented by 4 virtual visits via video conferencing
Number of subjects: 195

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Virtual house calls
Number of subjects: 195
Study: 25907250

Group type: EXPERIMENTAL
Intervention: Low dose haloperidol
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 455
Study: 24267860

Group type: EXPERIMENTAL
Intervention: Smoking-cessation support delivered by text message
Number of subjects: 25
Study: 21546309

Group type: EXPERIMENTAL
Intervention: Community-based voluntary counselling and testing (CBVCT)
Number of subjects: 6250

Group type: COMPARATOR
Intervention: Standard clinic-based voluntary counselling and testing (SVCT)
Number of subjects: 6250
Study: 19817193

Group type: EXPERIMENTAL
Intervention: Pizhen
Number of subjects: 320

Group type: COMPARATOR
Intervention: Massage (Control)
Number of subjects: 320
Study: 18632013

Group type: EXPERIMENTAL
Intervention: Lifestyle interventions and medication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cost-utility analyses
Number of subjects: 0
Study: 15119583

Group type: EXPERIMENTAL
Intervention: OptiBond Solo Plus (OP) with 15 s etching time
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Single Bond (SB) with 15 s etching time
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: OptiBond Solo Plus (OP) with 30 s etching time
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Single Bond (SB) with 30 s etching time
Number of subjects: 32

Group type: COMPARATOR
Intervention: Single Bond (SB)
Number of subjects: 32
Study: 11915638

Group type: EXPERIMENTAL
Intervention: 2-octyl cyanoacrylate bioadhesive
Number of subjects: 0
Study: 9728851

Group type: EXPERIMENTAL
Intervention: Isoflurane alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Large-dose esmolol (250 microg x kg(‐1) x min(‐1)) with isoflurane
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Alfentanil (effect site target of 50 ng/mL) with isoflurane
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Alfentanil with small-dose esmolol (50 microg x kg(‐1) x min(‐1))
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Alfentanil with large-dose esmolol
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Esmolol and alfentanil
Number of subjects: 100
Study: 9419752

Group type: EXPERIMENTAL
Intervention: Transdermal estrogen patch (TE2)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Transdermal estrogen patch with added medroxyprogesterone acetate (TE2/MPA)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 2195800

Group type: EXPERIMENTAL
Intervention: Pefloxacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gentamycin
Number of subjects: 0
Study: 55780

Group type: EXPERIMENTAL
Intervention: Oxprenolol (≤320 mg/day, increased to 960 mg if inadequate response)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Methyldopa (≤1 g/day, increased to 3 g if inadequate response)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 29
Study: 30852482

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg, 1 time/day
Number of subjects: 0
Study: 27889459

Group type: EXPERIMENTAL
Intervention: Music by David Tolley
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Music by Kevin Kern
Number of subjects: 138

Group type: COMPARATOR
Intervention: No music (control group)
Number of subjects: 138
Study: 26199710

Group type: EXPERIMENTAL
Intervention: Orally administered IV midazolam (0.5 mg/kg for children under 5 years, 0.2 mg/kg for patients over 5 years)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Commercially prepared midazolam syrup
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both groups (IV/Oral and syrup)
Number of subjects: 88
Study: 23604057

Group type: EXPERIMENTAL
Intervention: Thoracoscopic repair
Number of subjects: 20

Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Thoracoscopic repair for CDH
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Thoracoscopic repair for EA/TEF
Number of subjects: 20
Study: 16548949

Group type: EXPERIMENTAL
Intervention: N2O introduced after baseline blood gas measurements
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group continued breathing F(I O2) in nitrogen (N2)
Number of subjects: 20
Study: 12632292

Group type: EXPERIMENTAL
Intervention: Miflonide (Budesonide 400 ‐ 800 microg per day) and Foradil (Formoterol 24 ‐ 48 microg per day)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Miflonide/Foradil
Number of subjects: 80
Study: 10583852

Group type: EXPERIMENTAL
Intervention: Gastrin (15 pmol kg‐1 h‐1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Gastrin (15 pmol kg‐1 h‐1) with omeprazole pretreatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study: 8902042

Group type: EXPERIMENTAL
Intervention: Instructions to produce the sign language equivalent of each stimulus word
Number of subjects: 44

Group type: COMPARATOR
Intervention: Instructions to fingerspell each word
Number of subjects: 44

Group type: COMPARATOR
Intervention: Instructions to form a sign language sentence that included the stimulus word
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Stimulus words rated high in imagery value
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Immediate recall of words
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Delayed final recall
Number of subjects: 44
Study: 1794157

Group type: EXPERIMENTAL
Intervention: Continuous or unequal day-night terbutaline dosing (initial bolus doses of 1.47, 2.94, and 4.41 micrograms/kg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 45
Study: 6336954

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 29660034

Group type: EXPERIMENTAL
Intervention: E-cigarettes (Arm 1)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Placebo e-cigarettes (Arm 2)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control (Arm 3)
Number of subjects: 210
Study: 28709452

Group type: EXPERIMENTAL
Intervention: Augmented interaction group
Number of subjects: 88

Group type: COMPARATOR
Intervention: Limited interaction group
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both groups (augmented and limited interaction)
Number of subjects: 88
Study: 25598314

Group type: EXPERIMENTAL
Intervention: Tyrosine (TYR)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 22465743

Group type: EXPERIMENTAL
Intervention: Left prefrontal TMS at 120% of resting motor threshold
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Left prefrontal TMS with adjustments (1 cm forward)
Number of subjects: 185
Study: 21576052

Group type: EXPERIMENTAL
Intervention: Innovac Quick‐Draw device
Number of subjects: 278

Group type: COMPARATOR
Intervention: Traditional capillary blood draws
Number of subjects: 278
Study: 18996742

Group type: EXPERIMENTAL
Intervention: Sublingual zolpidem (10mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Oral zolpidem (10mg)
Number of subjects: 18
Study: 16999754

Group type: EXPERIMENTAL
Intervention: Postoperative autologous blood re-infusion system 1
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Postoperative autologous blood re-infusion system 2
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no re-infusion)
Number of subjects: 70
Study: 14532838

Group type: EXPERIMENTAL
Intervention: Trospium chloride (TCl) 10, 15, 20, or 25 mg daily for 21 days
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Trospium chloride (TCl)
Number of subjects: 58
Study: 10897047

Group type: EXPERIMENTAL
Intervention: Sequential regimen of doxorubicin and CMF
Number of subjects: 403

Group type: COMPARATOR
Intervention: Alternating regimen of doxorubicin and CMF
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: High TLI
Number of subjects: 403
Study: 8782125

Group type: EXPERIMENTAL
Intervention: Serum hyaluronic acid (HA) measurement
Number of subjects: 65

Group type: COMPARATOR
Intervention: Erythrocyte sedimentation rate (ESR)
Number of subjects: 65

Group type: COMPARATOR
Intervention: C reactive protein (CRP)
Number of subjects: 65
Study: 1281727

Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 6378743

Group type: EXPERIMENTAL
Intervention: 20 mg ISDN (isosorbide dinitrate) acute administration
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 20 mg ISDN (isosorbide dinitrate) during long-term treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control values during long-term treatment
Number of subjects: 10
Study: 29575708

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training with vascular occlusion (n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control exercise group (n = 15)
Number of subjects: 30
Study: 26453367

Group type: EXPERIMENTAL
Intervention: LA Sprouts (nutrition, cooking, and gardening intervention)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 304
Study: 24597620

Group type: EXPERIMENTAL
Intervention: Secukinumab 25 mg, 75 mg, 150 mg, 300 mg
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Secukinumab (all dose groups combined)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study: 22994224

Group type: EXPERIMENTAL
Intervention: Intensive level of glucose control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care glucose control
Number of subjects: 0
Study: 20068568

Group type: EXPERIMENTAL
Intervention: Cetuximab 400 mg/m² at first infusion followed by weekly infusions of 250 mg/m² combined with FUFOX (oxaliplatin 50 mg/m², 5-FU 2000 mg/m², and DL-folinic acid 200 mg/m²)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Cetuximab plus FUFOX
Number of subjects: 52
Study: 17331807

Group type: EXPERIMENTAL
Intervention: Provider education
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient education
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Provider/patient education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 15826417

Group type: EXPERIMENTAL
Intervention: Tranexamic acid 20 mg/kg on induction
Number of subjects: 64

Group type: COMPARATOR
Intervention: No tranexamic acid
Number of subjects: 64
Study: 12160267

Group type: EXPERIMENTAL
Intervention: Assessment of laryngoscopic findings associated with LPRD
Number of subjects: 120
Study: 10197834

Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy control men
Number of subjects: 20
Study: 7750382

Group type: EXPERIMENTAL
Intervention: Form-function correspondences
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Perceptual similarity motivated by intuitive beliefs about correspondences between form and function
Number of subjects: 2
Study: 2405107

Group type: EXPERIMENTAL
Intervention: Fluorouracil (FU) plus Cisplatin (CDDP)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Fluorouracil (FU) alone
Number of subjects: 122
Study: 6253122

Group type: EXPERIMENTAL
Intervention: Indomethacin (2 mg day‐1 kg‐1) given orally for 7 days
Number of subjects: 0
Study: 31902875

Group type: EXPERIMENTAL
Intervention: Bevacizumab (5 mg/kg administered intravenously four times with an inter-dose interval of 2 weeks)
Number of subjects: 10
Study: 31779678

Group type: EXPERIMENTAL
Intervention: Usual care with DMP
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Usual care with DMP plus M-POWER Rewards
Number of subjects: 339

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 339
Study: 29960291

Group type: EXPERIMENTAL
Intervention: Cervical spondylosis formula granules
Number of subjects: 499

Group type: COMPARATOR
Intervention: Jingfukang granules
Number of subjects: 499
Study: 25845867

Group type: EXPERIMENTAL
Intervention: 75 mg KAE609 plus 320 mg PPQ
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 25 mg KAE609 plus 1,280 mg PPQ
Number of subjects: 110

Group type: COMPARATOR
Intervention: PPQ alone (320 mg)
Number of subjects: 110

Group type: COMPARATOR
Intervention: KAE609 alone (25 mg)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: KAE609 and PPQ combination
Number of subjects: 110